Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.51
Bid: 3.02
Ask: 4.00
Change: 0.00 (0.00%)
Spread: 0.98 (32.45%)
Open: 3.51
High: 0.00
Low: 0.00
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

26 Jun 2020 11:00

RNS Number : 2148R
Proteome Sciences PLC
26 June 2020
 

26 June 2020

 

 

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Annual General Meeting (AGM) Statement

 

At the Company's AGM being held today at 11.00 am, the Chairman, Christopher Pearce, will make the following statement:

 

"Following the delivery of a profit after tax in 2019, we are pleased to report continued progress throughout the business. We have experienced good growth in services revenues and sales of both TMT® and TMTpro™ have remained stable over the first 5 months of the year. Despite the challenges of the COVID-19 pandemic, our dedicated staff have ensured we remained fully operational and have delivered 11 projects carried over from 2019 for which we already had samples. A further 10 projects are ongoing and new orders are also being generated. We expect these positive trends to continue through the rest of the year".

 

 

For further information:

 

Proteome Sciences plc

Dr Ian Pike, Interim Chief Executive Officer & Chief Scientific Officer

 

Richard Dennis, Chief Commercial Officer

Tel: +44 (0)20 7043 2116

 

Allenby Capital Limited (AIM Nominated Adviser & Broker)

John Depasquale / Jeremy Porter

Tel: +44 (0) 20 3328 5656

 

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGMFFMPTMTJTMJM
Date   Source Headline
13th Apr 200712:13 pmPRNNotifiable Interest
21st Mar 20077:00 amPRNHolding(s) in Company
21st Mar 20077:00 amPRNHolding(s) in Company
21st Mar 20077:00 amPRNHolding(s) in Company
21st Feb 20079:41 amPRNPress Release
19th Feb 20074:40 pmPRNHolding(s) in Company
15th Jan 20077:00 amPRNStatement re Issuance of Patent
5th Jan 200712:29 pmPRNHolding(s) in Company
21st Dec 20064:59 pmPRNHolding(s) in Company
18th Dec 20062:12 pmPRNStatement re: Patent
13th Dec 20062:07 pmPRNStatement re Issuance of Patent
13th Dec 200611:32 amPRNTotal Voting Rights
11th Dec 200610:49 amPRNStatement re: Issuance of Patent
31st Oct 200612:42 pmPRNHolding(s) in Company
30th Oct 20065:38 pmPRNBlocklisting
5th Sep 20069:54 amPRNDirectorate Change
27th Jul 20061:53 pmPRNHolding(s) in Company
27th Jul 200612:04 pmPRNResult of AGM
18th Jul 20067:00 amPRNAppointment
17th Jul 20064:41 pmRNSSecond Price Monitoring Extn
17th Jul 20064:36 pmRNSPrice Monitoring Extension
6th Jul 20065:12 pmPRNHolding(s) in Company
4th Jul 20064:42 pmRNSSecond Price Monitoring Extn
4th Jul 20064:36 pmRNSPrice Monitoring Extension
29th Jun 20062:00 pmPRNFinal Results
28th Jun 20064:42 pmRNSSecond Price Monitoring Extn
28th Jun 20064:36 pmRNSPrice Monitoring Extension
28th Jun 20064:32 pmPRNRe Licence Agreement
23rd May 20063:08 pmPRNRe Licence Agreement
26th Apr 20062:52 pmPRNBlocklisting
20th Apr 20064:39 pmPRNHolding(s) in Company
20th Apr 20064:36 pmPRNHolding(s) in Company
7th Apr 20065:20 pmRNSNotifiable Interest
22nd Mar 20064:00 pmPRNNotifiable Interest
22nd Feb 20062:30 pmRNSNotifiable Interest
13th Feb 20065:21 pmRNSNotifiable Interest Corrected
13th Feb 20065:18 pmRNSNotifiable Interest
10th Feb 20064:26 pmRNSNotifiable Interest
9th Feb 20068:30 amRNSNotifiable Interest
24th Jan 20064:32 pmRNSNotifiable Interest
25th Oct 20059:51 amPRNBlocklisting
26th Sep 200510:37 amPRNNotice of Results
5th Sep 20051:55 pmPRNHolding(s) in Company
23rd Jun 200511:18 amPRNHolding(s) in Company
20th Jun 200512:39 pmPRNHolding(s) in Company
16th Jun 20053:18 pmPRNHolding(s) in Company
7th Jun 20058:43 amPRNStatement re Grant of Options
3rd Jun 20053:32 pmPRNCorrection : Final Results
3rd Jun 20057:04 amPRNFinal Results
13th May 20051:37 pmPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.